Clinical trials: Atopic Eczema
Atopic Dermatitis
Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis
Atopic dermatitis is one of the most frequent skin diseases. The disease is often worst during winter months when the skin is drier. Mild to moderate cases of atopic dermatitis are often controlled by a moisturizer alone.
- Trial name
- NCT00931411
- Testing
- Formulation 609580 20, Formulation 609209 (Lipikar Baume)
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Cosmetique Active International
Atopic Dermatitis Eczema
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).
- Trial name
- NCT04773600
- Testing
- Roflumilast Cream, Vehicle cream
- Where
- 53 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis.
- Trial name
- NCT04271514
- Testing
- RPT193
- Where
- 14 sites in United States, Netherlands
- Volunteers
- 103 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Atopic Dermatitis
A Study Evaluating APG777 in Atopic Dermatitis
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD).
- Trial name
- NCT06395948
- Testing
- APG777
- Where
- 94 sites in United States, Canada and 7 more
- Volunteers
- 470 people
- Sponsor
- Apogee Therapeutics, Inc.
Psoriasis, Atopic Dermatitis
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic…
- Trial name
- NCT01137032
- Testing
- Pandel Cream 0.1%
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Eczema Atopic Dermatitis, Eczema
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
This is a Phase 2, two-stage, adaptive, 1:1 randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy, safety, and tolerability of GX-03 topical ointment in adult subjects with atopic dermatitis…
- Conditions
- Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
- Trial name
- GX-03 in AD (NCT07355075)
- Testing
- GX-03, Vehicle
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- Turn Therapeutics
Moderate to Severe Atopic Dermatitis
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.
- Trial name
- NCT07370909
- Testing
- LW402
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
Dermatitis, Atopic
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.
- Trial name
- NCT00152464
- Testing
- Levocetirizine
- Volunteers
- 514 people
- Sponsor
- UCB Pharma SA
Dermatitis, Atopic
Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD
The aim of the study is to collect different parameters (clinical, biological and biometrological) of Atopic Dermatitis (AD) in order to identify which factors are modified during the flare-up phase.
- Trial name
- NCT05639738
- Testing
- Clinical and instrumental measurements
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream
The principle aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 39652 cream is administered cutaneously as single dose to subjects with atopic dermatitis and to healthy subjects.
- Trial name
- NCT01850849
- Testing
- LEO 39652 cream, cream vehicle
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.
The purpose of this Phase Ib study is to investigate the safety, tolerability and pharmacokinetics of LEO 29102 2,5 mg/g cream when treating atopic dermatitis (AD) lesions from 10 up to 100% of the body surface area (BSA) twice…
- Trial name
- NCT01447758
- Testing
- LEO 29102, LEO 29102 Cream Vehicle
- Where
- 8 sites in Germany
- Volunteers
- 58 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
Clinical data suggest that treatment with OM-85, by inducing an early contact with bacterial extracts, could modulate the immunity of children with Atopic Dermatitis, and thus play an active role in the treatment of Atopic…
- Trial name
- NCT05222516
- Testing
- Broncho-Vaxom
- Where
- 28 sites in France, Germany and 2 more
- Volunteers
- 63 people
- Sponsor
- OM Pharma SA
Atopic Dermatitis
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
- Trial name
- NCT06345404
- Testing
- Soquelitinib
- Where
- 16 sites in United States
- Volunteers
- 82 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Atopic Dermatitis
Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis
To compare the efficacy of a JW-100 cream with active control (commercially available as EUCRISA®, Pfizer) for the treatment of atopic dermatitis (AD) in adult patients with mild to moderate AD measured with the Investigator's…
- Trial name
- NCT05016284
- Testing
- JW-100, Eucrisa
- Where
- Brazil
- Sponsor
- Applied Biology, Inc.
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.
The purpose of the study is to evaluate the Safety, Tolerability, and Pharmacokinetics of LNK01004 ointment (0.3%, 1.0%, and 1.5%) vs vehicle twice daily (BID) in Adults Patients with Atopic Dermatitis.
- Trial name
- NCT06553287
- Testing
- LNK01004 ointment 0.3%, LNK01004 ointment 1.0%, LNK01004 ointment 1.5%
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Atopic Dermatitis
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
The purpose of this study is to assess the pharmacokinetic parameters and safety of topical MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use conditions.
- Trial name
- NCT02945657
- Testing
- MM36 topical ointment, 1%
- Where
- 12 sites in United States, Honduras and 1 more
- Volunteers
- 32 people
- Sponsor
- Medimetriks Pharmaceuticals, Inc
Atopic Dermatitis, Atopic Hand Eczema
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
The purpose of this study is to test if treatment with tralokinumab is safe and efficacious in treating moderate-to-severe atopic hand eczema.
- Trial name
- ADHAND (NCT05958407)
- Testing
- Tralokinumab
- Where
- 69 sites in United States, Belgium and 8 more
- Volunteers
- 235 people
- Sponsor
- LEO Pharma
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study.
- Trial name
- JADE EXTEND (NCT03422822)
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 539 sites in United States, Argentina and 26 more
- Volunteers
- 3,166 people
- Sponsor
- Pfizer
Moderate-to-severe Atopic Dermatitis
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moderate-severe AD subjects.
- Trial name
- NCT05186922
- Testing
- CM326
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
LEO19123 Cream in the Treatment of Atopic Dermatitis
To compare the efficacy and safety of two different dose combinations of LEO19123 (calcipotriol and LEO80122) with LEO19123 cream vehicle for 3 weeks in the treatment of patients with atopic dermatitis
- Trial name
- NCT00392067
- Testing
- Calcipotriol and LEO80122 (LEO19123 cream)
- Where
- 4 sites in Canada, Denmark and 2 more
- Volunteers
- 75 people
- Sponsor
- LEO Pharma